

## Oral Direct Thrombin Inhibitor Reversal Guidelines

### Life threatening bleeding

- Hold oral direct thrombin inhibitor (ex: dabigatran)
- Reversal Agent
  - Idarucizumab (PRAXBIND)
    - Recommended dose: 5 grams IV ONE TIME (as separate 2.5 mg doses, no more than 15 min apart)
    - If clinically relevant bleeding occurs with elevated coagulation parameters after initial dose, may consider administration of an additional 5 gram dose of Idarucizumab (PRAXBIND). Safety and effectiveness of repeat treatment with Idarucizumab (PRAXBIND) has not been established.
- Other: Empiric treatment
  - Oral activated charcoal may be used within 1- 2 hours of ingestion of dabigatran
  - Supportive measures include: fluid and blood product (RBC) replacement, mechanical compression, surgical intervention
  - Maintain adequate diuresis to protect the renal excretion of dabigatran
  - Hemodialysis may be considered in certain circumstances (renal failure, overdose); dabigatran is *only 35%* protein-bound.
    - Note: With a creatinine clearance greater than 80 mL/min, dabigatran's half-life is approximately 12 hours. Half-life increases with worsening renal function and is up to 34 hours in creatinine clearance less than 30 mL/min
  - FFP has not been shown to be effective in reversing the effects of dabigatran except in the setting of a documented dilutional coagulopathy
  - Monitor: aPTT